Who We Are
KELIX bio, a wholly owned subsidiary of Mubadala Investment Company, is a leading specialty pharmaceutical company providing complex generics and biosimilars globally. Since its integration into Mubadala, KELIX Bio has become a significant player in the life sciences sector, strategically acquiring leading pharmaceutical assets, including Bioventure, Bioventure Healthcare, Gulf Inject, and Wellpharma, further strengthening its position in biologics.
Present in
40+
countries
Our Subsidiaries
Based in Cairo, Adwia is Egypt’s leading generics pharmaceutical company with leading brands in the CNS, men’s health pain, and anti-infectives.
See more
Based in Hyderabad, Celon is one of India’s leading specialty pharmaceutical companies focused on Oncology and Critical Care.
See more
KELIX bio Malta, is a state-of-the-art manufacturing facility dedicated to producing liquid and freeze-dried cytotoxic drug products.
See more
Based in Rabat, PHI is one of Morocco’s largest generics company, primarily selling locally to the Moroccan market, with a high quality oral solid manufacturing infrastructure.
See more
Based in UAE, Bioventure Healthcare is the region’s largest manufacturer of soft gelatin capsules for pharmaceutical and supplement products with expansion underway into oral solids and injectables.
See more
Based in UAE, Bioventure is a company that specializes in biotech and generics commercialization, as well as tech transfer and in/out-licensing activities.
See more
Based in UAE, Gulf Inject is specialized in the manufacturing of sterile fluid management therapy, parenteral therapy and sterile healthcare solutions.
See more
Based in UAE, Wellpharma is a leader specialized in the production of intravenous (IV) and dialysis products, as well as other therapeutic products that span across a total range of 50 products.
See more